News

Caretaker Medical Receives Inaugural Healthcare Tech Innovation Award and $200,000 Grant from Medical Society of D.C.

Caretaker Medical is honored to announce it has been awarded the Healthcare Technology Innovation Award, along with a $200,000 grant, from the Medical Society of the District of Columbia (MSDC) at the 5th annual Capital Healthcare Honors Gala. This prestigious award, presented on March 26, 2025, recognizes Caretaker Medical’s groundbreaking work in advancing wireless patient monitoring with its VitalStream platform.

The award, supported by a grant from The Institute for Technology in Healthcare, commemorates the legacy of Dr. Cesar A. C. Caceres, an esteemed medical professional dedicated to the application of technology to solve healthcare challenges. Dr. Caceres founded the Institute for Technology in Healthcare and was recognized for his pioneering work in computer-electrocardiographic interpretive systems.

“We are delighted to celebrate the memory and achievements of Dr. Caceres by presenting Caretaker Medical with this inaugural award,” said Matthew Lecuyer, MD, Healthy Physician Foundation board chair. “As technology improves patient care and physician wellbeing, this award connects the achievements of the past with the promise of the future.”

Caretaker Medical’s CEO, Jeff Pompeo, accepted the award on behalf of the company, expressing gratitude for the recognition of their commitment to improving patient care and physician health. “This award validates our dedication to providing patients and physicians with a much-needed wearable, continuous blood pressure monitoring solution,” said Pompeo.

VitalStream, Caretaker Medical’s US Food and Drug Administration-cleared wearable monitor, merges clinical accuracy with a wire-free, comfortable patient experience. The $200,000 grant will support the expansion of this innovative platform, which provides continuous blood pressure and hemodynamic monitoring.

The technology has demonstrated versatility in routine care and crisis response, proving invaluable in applications such as maternal health monitoring, perioperative recovery, and during the recent IV fluid shortages caused by Hurricane Helene. In these challenging times, VitalStream has helped healthcare providers maintain continuous blood pressure monitoring, ensuring patient safety and optimizing fluid management.

“VitalStream offers significant advantages for patients and providers in routine conditions, as well as unexpected and demanding circumstances,” said Johnny Mann, vice president of sales and marketing at Caretaker Medical. “Our technology can help ensure patient safety and optimize fluid management during some of the most challenging times.”

Caretaker Medical extends its deepest gratitude to the MSDC and The Institute for Technology in Healthcare for this honor and for their tireless efforts to advance healthcare in the Nation’s Capital Region and beyond.

Learn more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin